Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles

Clinical Chemistry

Volumn 48, Issue 9, 2002, Pages 1460-1471

  Moyer, Thomas P ^a   Charlson, Joel R ^a   Enger, Robert J ^a   Dale, Lowell C ^a   Ebbert, Jon O ^a   Schroeder, Darrell R ^a   Hurt, Richard D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; ANABASINE; COTININE; NICOTINE; NORNICOTINE;

ABSTINENCE; ACCURACY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; METABOLITE; NICOTINE REPLACEMENT THERAPY; QUANTITATIVE ANALYSIS; SMOKING CESSATION; TANDEM MASS SPECTROMETRY; TOBACCO DEPENDENCE; URINE LEVEL;

NICOTIANA TABACUM;

EID: 0036720952     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.9.1460     Document Type: Article

References (47)

1. The human pharmacology of nicotine
2. Prying open the door to the tobacco industry's secrets about nicotine. The Minnesota tobacco trial
3. Pharmacology of nicotine: Addiction and therapeutics
4. Individual differences in nicotine kinetics and metabolism in humans
5. Nicotine delivery kinetics and abuse liability
6. Clinical pharmacokinetics of nicotine
7. Tobacco smoking and nicotine dependence
8. Bupropion for the treatment of nicotine dependence in spit tobacco users
9. Cotinine as a marker for nicotine exposure in spit tobacco users
10. Nicotine renal excretion rate influences nicotine intake during cigarette smoking
11. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy
12. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
13. Application of urine nicotine and cotinine excretion rates to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy
14. Drug therapy to aid in smoking cessation - Tips on maximizing patients' chances for success
15. Treatment of nicotine dependence
16. CYP2D6 phenotype and the metabolism of nicotine and cotinine
17. In vitro-in vivo correlations of human (S)-nicotine metabolism
18. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the Δ1′,5′-nicotinium ion
19. Inhibition of nicotine's metabolism: A potential new treatment for tobacco dependence
20. Metabolism of nicotine to cotinine studied by a dual stable isotope method
21. Serum nicotine and cotinine levels during nicotine-patch therapy
22. Recent studies of nicotine metabolism in humans
23. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers
24. A new gas chromatography-mass spectrometry method for simultaneous determination of total and free trans-3′-hydroxycotinine and cotinine in the urine of subjects receiving transdermal nicotine
25. Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users
26. Minor tobacco alkaloids as biomarkers for tobacco use: Comparison of users of cigarettes, smokeless tobacco, cigars, and pipes
27. Transdermal nicotine for mildly to moderately active ulcerative colitis
28. Nicotine nasal spray for smoking cessation: Pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels
29. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms
30. Nicotine patch use in pregnant smokers: Nicotine and cotinine levels and fetal effects
31. Smoking cessation rates in active and recovering alcoholics treated for nicotine dependence
32. Nicotine patch therapy in 101 adolescent smokers - Efficacy, withdrawal symptom relief, carbon monoxide and plasma cotinine levels
33. Short-term treatment with transdermal nicotine affects functions of canine saphenous veins
34. Time and dose-effect of transdermal nicotine on endothelial function
35. Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts
36. Modulation of nitric-oxide synthase by nicotine
37. Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler
38. Nicotine patch use in pregnant smokers - Smoking abstinence and delivery outcomes
39. A solid phase extraction method for determination of nicotine in serum and urine by isotope dilution gas chromatography/mass spectrometry with selected ion monitoring
40. Quantification of cotinine in plasma and saliva by liquid chromatography
41. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
42. Analysis of nicotine, 3-hydroxycotinine, cotinine, and caffeine in urine of passive smokers by HPLC-tandem mass spectrometry
43. Use of urine cotinine to validate smoking self-reports in U.S. Navy recruits
44. Predictors of smoking cessation among elderly smokers treated for nicotine dependence
45. Misclassification of smoking status among women in relations to exposure to environmental tobacco smoke
46. Urinary cotinine as a tobacco-smoke exposure index: A minireview